cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Graphite Bio Inc
3 own
3 watching
Current Price
$2.22
$-0.01
(-0.45%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
129.09M
52-Week High
52-Week High
11.3
52-Week Low
52-Week Low
1.59
Average Volume
Average Volume
0.15M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization129.09M
icon52-Week High11.3
icon52-Week Low1.59
iconAverage Volume0.15M
iconDividend Yield--
iconP/E Ratio--
What does the Graphite Bio Inc do?
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More
How much money does Graphite Bio Inc make?
News & Events about Graphite Bio Inc.
Zolmax
3days ago
Graphite Bio (NASDAQ:GRPH Get Rating) had its target price lowered by Morgan Stanley from $6.00 to $3.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts have also issued research reports about the stock...
Ticker Report
1month ago
BMO Capital Markets downgraded shares of Graphite Bio (NASDAQ:GRPH Get Rating) from an outperform rating to a market perform rating in a report published on Friday, Marketbeat reports. BMO Capital Markets currently has $7.00 price target on the stock, down from their previous price target of...
Benzinga
1month ago
Graphite Bio's (NASDAQ:GRPH) short percent of float has fallen 3.92% since its last report. The company recently reported that it has 1.25 million shares sold short, which is 5.64% of all regular shares that are available for trading. read more...
Ticker Report
1month ago
Shares of Graphite Bio, Inc. (NASDAQ:GRPH Get Rating) have been assigned a consensus rating of Moderate Buy from the seven research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have...
Business Wire
2 months ago
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical results supporting the use of a single-cell...
Frequently Asked Questions
Frequently Asked Questions
What is Graphite Bio Inc share price today?
plus_minus_icon
Can Indians buy Graphite Bio Inc shares?
plus_minus_icon
How can I buy Graphite Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Graphite Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Graphite Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Graphite Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Graphite Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Graphite Bio Inc?
plus_minus_icon
What percentage is Graphite Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Graphite Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.22
$-0.01
(-0.45%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00